Charles Schwab
LYRA

Charles Schwab’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Charles Schwab’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,232
Closed -$14.1K – 3536
2025
Q1 		$14.1K Hold
2,232
– – ﹤0.01% 3469
2024
Q4 		$23K Hold
2,232
– – ﹤0.01% 3482
2024
Q3 		$28.7K Hold
2,232
– – ﹤0.01% 3466
2024
Q2 		$30.9K Buy
+2,232
New +$252K ﹤0.01% 3561
2021
Q2 		– Sell
-284
Closed -$165K – 3485
2021
Q1 		$165K Hold
284
– – ﹤0.01% 3340
2020
Q4 		$162K Buy
+284
New +$160K ﹤0.01% 3280

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's LYRA Position: Q2 2025 in Review

Charles Schwab sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 2,232 shares — an estimated $14.1K sold.

Charles Schwab first reported a position in LYRA in Q4 2020 and held it in 6 quarters. The position peaked at $165K in Q1 2021. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • Charles Schwab reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 2,232 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $14.1K.
  • Charles Schwab first reported a position in LYRA THERAPEUTICS INC in Q4 2020 and held it in 6 quarters.
  • Charles Schwab's LYRA THERAPEUTICS INC position peaked at $165K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.